Soleno Therapeutics (SLNO) Accumulated Expenses (2013 - 2026)
Soleno Therapeutics (SLNO) reported Accumulated Expenses of $5.7 million for Q1 2026, up 33.81% year-over-year from $4.3 million in Q1 2025, and down 40.86% on a QoQ basis from $9.7 million in Q4 2025.
Soleno Therapeutics (SLNO) has 14 years of Accumulated Expenses data on file, last reported at $5.7 million in Q1 2026.
- Quarterly Accumulated Expenses rose 33.81% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (up 33.81% YoY) and the FY2025 annual result came in at $9.7 million, up 102.62% from the prior year.
- Accumulated Expenses fell to $5.7 million in Q1 2026 per SLNO's latest filing, from $9.7 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $9.7 million in Q4 2025 and bottomed at $409000.0 in Q2 2025.
- The 5-year median for Accumulated Expenses is $1.7 million (2022), against an average of $2.9 million.
- Peak annual rise in Accumulated Expenses reached 248.86% in 2025, while the deepest fall reached 80.97% in 2025.
- Tracing SLNO's Accumulated Expenses over 5 years: stood at $1.7 million in 2022, then surged by 87.16% to $3.1 million in 2023, then jumped by 52.34% to $4.8 million in 2024, then soared by 102.62% to $9.7 million in 2025, then plunged by 40.86% to $5.7 million in 2026.
- Per Business Quant, the three latest SLNO Accumulated Expenses figures stand at $5.7 million (Q1 2026), $9.7 million (Q4 2025), and $7.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.72 Mn |
| Dec 31, 2025 | 9.68 Mn |
| Sep 30, 2025 | 7.25 Mn |
| Jun 30, 2025 | 409,000.00 |
| Mar 31, 2025 | 4.28 Mn |
| Dec 31, 2024 | 4.78 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 2.15 Mn |
| Mar 31, 2024 | 1.23 Mn |
| Dec 31, 2023 | 3.14 Mn |
| Sep 30, 2023 | 1.50 Mn |
| Jun 30, 2023 | 1.17 Mn |
| Mar 31, 2023 | 721,000.00 |
| Dec 31, 2022 | 1.68 Mn |
| Sep 30, 2022 | 1.28 Mn |
| Jun 30, 2022 | 932,000.00 |
| Mar 31, 2022 | 598,000.00 |
| Dec 31, 2021 | 728,000.00 |
| Sep 30, 2021 | 809,000.00 |
| Jun 30, 2021 | 652,000.00 |
| Mar 31, 2021 | 411,000.00 |
| Dec 31, 2020 | 1.01 Mn |
| Sep 30, 2020 | 756,000.00 |
| Jun 30, 2020 | 520,000.00 |
| Mar 31, 2020 | 338,000.00 |
| Dec 31, 2019 | 283,000.00 |
| Sep 30, 2019 | 1.72 Mn |
| Jun 30, 2019 | 1.12 Mn |
| Mar 31, 2019 | 992,000.00 |
| Dec 31, 2018 | 274,000.00 |
| Sep 30, 2018 | 1.15 Mn |
| Jun 30, 2018 | 862,000.00 |
| Mar 31, 2018 | 721,000.00 |
| Dec 31, 2017 | 973,000.00 |
| Sep 30, 2017 | 976,000.00 |
| Jun 30, 2017 | 879,000.00 |
| Mar 31, 2017 | 1.24 Mn |
| Dec 31, 2016 | 1.05 Mn |
| Sep 30, 2016 | 915,000.00 |
| Jun 30, 2016 | 944,000.00 |
| Mar 31, 2016 | 1.32 Mn |
| Dec 31, 2015 | 1.63 Mn |
| Sep 30, 2015 | 1.22 Mn |
| Jun 30, 2015 | 1.22 Mn |
| Mar 31, 2015 | 438,000.00 |
| Dec 31, 2014 | 201,457.00 |
| Sep 30, 2014 | 358,000.00 |
| Dec 31, 2013 | 128,651.00 |